HCM HUTCHMED (China) Limited

LSE · GB · Healthcare · Drug Manufacturers - Specialty & Generic · hutch-med.com

214.00GBp-0.47%Mkt Cap: 2.02B $P/E: 214.00Today

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and …

Headline	Source	Time
Today
Can Hutchmed (LSE:HCM) Open A New US Lung Cancer Chapter After Filing Its Orpathys And Tagrisso Application This Week As FTSE 100 Slips?	Kalkine Media	9h
Older
HUTCHMED (China) Limited (0013.HK) Stock Price, News, Quote & History	Yahoo! Finance Canada	Oct 3
HUTCHMED (China) Ltd (HCM) Shares Surge 3.4% -- What GF Score of 79 Tells Investors	GuruFocus	Oct 1
GSK has a pending deal for rights to a cancer drug HUTCHMED (HCM) has dosed in its first patient.	Stock Titan	Sep 29
Hutchmed says AstraZeneca files US application for Orpathys	London South East	Sep 29
Hutchmed Lung-Cancer Fighting Drug Submitted to FDA for Approval	marketscreener.com	Sep 29
RCS - Hutchmed China Ltd - Submission of US NDA for ORPATHYS® plus TAGRISSO	TradingView	Sep 29
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination	Reuters	Sep 29
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus	globenewswire.com	Sep 29
IN BRIEF: Hutchmed begins phase Ia trial of HMPL-A830 in China	London South East	Sep 28
Why is HUTCHMED China stock gaining today? By Investing.com	Investing.com UK	Sep 28
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors	Yahoo! Finance Canada	Sep 28
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody	GlobeNewswire	Sep 28
HUTCHMED (China) Ltd (HCM) Shares Fall 3.3% -- What GF Score of 79 Tells Investors	GuruFocus	Sep 25
GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHMED receives a $110 million upfront payment, potential milestone payments up to $1.3 billion, and tiered royalties on net sales, while granting GSK worldwide rights […]	Insider Monkey	Sep 24
GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity	Yahoo Finance	Sep 24
HUTCHMED stock falls 2.75 percent despite new ESMO data	AD HOC NEWS	Sep 24
RCS - Hutchmed China Ltd - Data to be Presented at ESMO 2026	TradingView	Sep 24
RCS - Hutchmed China Ltd - Data to be Presented at ESMO 2026	TradingView	Sep 24
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026	GlobeNewswire	Sep 24
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages	MarketBeat	Sep 18
HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript	Benzinga	Sep 18
HUTCHMED (China) Limited stock gains on GSK licensing deal for cancer drug HMPL-A830 - ad-hoc-news.de		Sep 17
HUTCHMED (NASDAQ:HCM) Sees Large Volume Increase - Should You Buy?	MarketBeat	Sep 14
HUTCHMED (China) Ltd (HCM) Stock Down 3.2% -- Now Undervalued? G	GuruFocus	Sep 11
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 - Slideshow (NASDAQ:HCM) 2026-09-07	Seeking Alpha	Sep 8
China's Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy	BBioSpectrum Asia	Sep 4
HUTCHMED grants GSK rights to cancer drug candidate	BBioXconomy	Sep 4
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfr	MarketBeat	Sep 3
HUTCHMED (China): $1.3B GSK deal accelerates global KRAS-EGFR therapy, validating ATTC platform and pipeline	TradingView	Sep 3
Hutchmed rises on $1.3bn KRAS licensing deal with GSK	Ppharmaphorum	Sep 3
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal	Proactive financial news	Sep 3
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug	Reuters	Sep 3
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to...	Proactive	Sep 3
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. HUTCHMED will receive US$110 million upfront and...	Proactive	Sep 3
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal	Proactive Investors	Sep 3
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal	Proactive Investors	Sep 3
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal	Proactive financial news	Sep 3
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug	Yahoo Finance	Sep 3
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy	GlobeNewswire	Sep 3
IN BRIEF: Hutchmed "thrilled" by positive phase 3 trial results	London South East	Sep 1
Lung cancer combo succeeds in first-line China trial	TThe Pharma Letter	Sep 1
AstraZeneca and HUTCHMED report Phase III results for Tagrisso-Orpathys combination	Yahoo Finance UK	Sep 1
HUTCHMED (HCM) lung cancer combo tops China Phase III trial	Stock Titan	Aug 31
HutchMed’s Atled wins China approval for FGFR2-driven bile duct cancer	AAllSci	Aug 31
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China	Yahoo Finance	Aug 31
Price to book forward of HUTCHMED (China) Limited – HKEX:13	TradingView	Aug 30
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China	GlobeNewswire	Aug 30
Hutchmed wins China approval for ATLED	TThe Pharma Letter	Aug 30
China grants conditional OK to HUTCHMED (HCM) ATLED after 42.5% response	Stock Titan	Aug 28

HCM HUTCHMED (China) Limited

Industry Peers